Targeting Cullin-RING ligases by MLN4924 induces autophagy via modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR axis

Cell Death and Disease

Volumn 3, Issue 9, 2012, Pages

  Zhao, Y ^a   Xiong, X ^a   Jia, L ^a,b   Sun, Y ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b FUDAN UNIVERSITY   (China)

Author keywords

Autophagy; CRL E3 ligases; Cullin neddylation; DEPTOR; HIF1 ; mTOR

Indexed keywords

[4 [4 [(2,3 DIHYDRO 1H INDEN 1 YL)AMINO] 7H PYRROLO[2,3 D]PYRIMIDIN 7 YL] 2 HYDROXYCYCLOPENTYLMETHYL] SULFAMATE; CULLIN RING E3 UBIQUITIN LIGASE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; AUTOPHAGY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; GENE INACTIVATION; HUMAN; HUMAN CELL; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL;

AUTOPHAGY; CELL LINE, TUMOR; CYCLOPENTANES; HCT116 CELLS; HELA CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MCF-7 CELLS; MICROTUBULE-ASSOCIATED PROTEINS; MULTIPROTEIN COMPLEXES; PYRIMIDINES; RNA INTERFERENCE; RNA, SMALL INTERFERING; TOR SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 84867204635     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.125     Document Type: Article

References (48)

1. Deshaies RJ, Joazeiro CA. RING domain E3 ubiquitin ligases. Annu Rev Biochem 2009; 78: 399-434.
2. Sarikas A, Hartmann T, Pan ZQ. The cullin protein family. Genome Biol 2011; 12: 220.
3. Zheng N, Schulman BA, Song L, Miller JJ, Jeffrey PD, Wang P et al. Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature 2002; 416: 703-709. (Pubitemid 34429140)
4. Jin J, Cardozo T, Lovering RC, Elledge SJ, Pagano M, Harper JW. Systematic analysis and nomenclature of mammalian F-box proteins. Genes Dev 2004; 18: 2573-2580. (Pubitemid 39453096)
5. Wu K, Fuchs SY, Chen A, Tan P, Gomez C, Ronai Z et al. The SCF(HOS/beta-TRCP)- ROC1 E3 ubiquitin ligase utilizes two distinct domains within CUL1 for substrate targeting and ubiquitin ligation. Mol Cell Biol 2000; 20: 1382-1393. (Pubitemid 30069258)
6. Duda DM, Borg LA, Scott DC, Hunt HW, Hammel M, Schulman BA. Structural insights into NEDD8 activation of cullin-RING ligases: conformational control of conjugation. Cell 2008; 134: 995-1006.
7. Deshaies RJ, Emberley ED, Saha A. Control of cullin-ring ubiquitin ligase activity by nedd8. Subcell Biochem 2010; 54: 41-56.
8. Soucy TA, Dick LR, Smith PG, Milhollen MA, Brownell JE. The NEDD8 conjugation pathway and its relevance in cancer biology and therapy. Genes Cancer 2010; 1: 708-716.
9. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009; 458: 732-736.
10. Brownell JE, Sintchak MD, Gavin JM, Liao H, Bruzzese FJ, Bump NJ et al. Substrateassisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol Cell 2010; 37: 102-111.
11. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008; 14: 1649-1657. (Pubitemid 351469448)
12. Wei D, Li H, Yu J, Sebolt JT, Zhao L, Lawrence TS et al. Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. Cancer Res 2012; 72: 282-293.
13. Soucy TA, Smith PG, Rolfe M. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clin Cancer Res 2009; 15: 3912-3916.
14. Milhollen MA, Traore T, Adams-Duffy J, Thomas MP, Berger AJ, Dang L et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood 2010; 116: 1515-1523.
15. Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E et al. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood 2010; 115: 3796-3800.
16. Tan M, Li Y, Yang R, Xi N, Sun Y. Inactivation of SAG E3 ubiquitin ligase blocks embryonic stem cell differentiation and sensitizes leukemia cells to retinoid acid. PLoS One 2011; 6: e27726.
17. Milhollen MA, Narayanan U, Soucy TA, Veiby PO, Smith PG, Amidon B. Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover. Cancer Res 2011; 71: 3042-3051.
18. Jia L, Li H, Sun Y. Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression. Neoplasia 2011; 13: 561-569.
19. Lin HK, Chen Z, Wang G, Nardella C, Lee SW, Chan CH et al. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 2010; 464: 374-379.
20. Lin JJ, Milhollen MA, Smith PG, Narayanan U, Dutta A. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res 2010; 70: 10310-10320.
21. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009; 137: 873-886.
22. Zhao Y, Xiong X, Sun Y. DEPTOR, an mTOR inhibitor, is a physiological substrate of SCF(betaTrCP) E3 ubiquitin ligase and regulates survival and autophagy. Mol Cell 2011; 44: 304-316.
23. Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy research. Cell 2010; 140: 313-326.
24. Bowman EJ, Siebers A, Altendorf K. Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. Proc Natl Acad Sci USA 1988; 85: 7972-7976.
25. Jung CH, Ro SH, Cao J, Otto NM, Kim DH. mTOR regulation of autophagy. FEBS Lett 2010; 584: 1287-1295.
26. Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 2010; 40: 310-322.
27. Duan S, Skaar JR, Kuchay S, Toschi A, Kanarek N, Ben-Neriah Y et al. mTOR generates an auto-amplification loop by triggering the betaTrCP- and CK1alpha-dependent degradation of DEPTOR. Mol Cell 2011; 44: 317-324.
28. Gao D, Inuzuka H, Tan MK, Fukushima H, Locasale JW, Liu P et al. mTOR drives its own activation via SCF(betaTrCP)-dependent degradation of the mTOR inhibitor DEPTOR. Mol Cell 2011; 44: 290-303.
29. Mao JH, Kim IJ, Wu D, Climent J, Kang HC, DelRosario R et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science 2008; 321: 1499-1502.
30. Hu J, Zacharek S, He YJ, Lee H, Shumway S, Duronio RJ et al. WD40 protein FBW5 promotes ubiquitination of tumor suppressor TSC2 by DDB1-CUL4-ROC1 ligase. Genes Dev 2008; 22: 866-871. (Pubitemid 351482839)
31. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M et al. HIFalpha targeted for VHLmediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001; 292: 464-468. (Pubitemid 32335941)
32. Jin HO, An S, Lee HC, Woo SH, Seo SK, Choe TB et al. Hypoxic condition- and high cell density-induced expression of Redd1 is regulated by activation of hypoxia-inducible factor- 1alpha and Sp1 through the phosphatidylinositol 3-kinase/Akt signaling pathway. Cell Signal 2007; 19: 1393-1403. (Pubitemid 46818907)
33. Regazzetti C, Bost F, Le Marchand-Brustel Y, Tanti JF, Giorgetti-Peraldi S. Insulin induces REDD1 expression through hypoxia-inducible factor 1 activation in adipocytes. J Biol Chem 2010; 285: 5157-5164.
34. Katiyar S, Liu E, Knutzen CA, Lang ES, Lombardo CR, Sankar S et al. REDD1, an inhibitor of mTOR signalling, is regulated by the CUL4A-DDB1 ubiquitin ligase. EMBO Rep 2009; 10: 866-872.
35. Iyer NV, Kotch LE, Agani F, LeungSW, Laughner E,Wenger RH et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 1998; 12: 149-162. (Pubitemid 28060446)
36. Kuma A, Hatano M, Matsui M, Yamamoto A, Nakaya H, Yoshimori T et al. The role of autophagy during the early neonatal starvation period. Nature 2004; 432: 1032-1036. (Pubitemid 40052234)
37. Chen HY, White E. Role of autophagy in cancer prevention. Cancer Prev Res (Phila) 2011; 4: 973-983.
38. Wirawan E, Vanden Berghe T, Lippens S, Agostinis P, Vandenabeele P. Autophagy: for better or for worse. Cell Res 2012; 22: 43-61.
39. Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002; 110: 177-189. (Pubitemid 34876546)
40. Eisenberg-Lerner A, Bialik S, Simon HU, Kimchi A. Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death Differ 2009; 16: 966-975.
41. Notte A, Leclere L, Michiels C. Autophagy as a mediator of chemotherapy-induced cell death in cancer. Biochem Pharmacol 2011; 82: 427-434.
42. Luo Z, Yu G, Lee HW, Li L, Wang L, Yang D et al. The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth. Cancer Res 2012; 72: 3360-3371.
43. Yang D, Li L, Liu H, Wu L, Luo Z, Li H et al. Induction of autophagy and senescence by knockdown of ROC1 E3 ubiquitin ligase to suppress the growth of liver cancer cells. Cell Death Differ 2012; doi:10.1038/cdd.2012.113.
44. Zhao Y, Sun Y. Targeting the mTOR-DEPTOR pathway by CRL E3 ubiquitin ligases: therapeutic application. Neoplasia 2012; 14: 360-367.
45. Bockbrader KM, Tan M, Sun Y. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL-and etoposide-induced apoptosis in breast cancer cells. Oncogene 2005; 24: 7381-7388. (Pubitemid 41622242)
46. Abramoff MD, Maglhaes PJ, Ram SJ. Image processing with ImageJ. Biophotonics Int 2004; 11: 36-42.
47. Sancak Y, Thoreen CC, Peterson TR, RA Lindquist, Kang SA, Spooner E et al. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 2007; 25: 903-915. (Pubitemid 46436534)
48. Wang Z, Sun Y. Identification and characterization of two splicing variants of human Noxa. Anticancer Res 2008; 28: 1667-1674. (Pubitemid 351892942)